长链非编码RNA表达与肺腺癌血管内皮功能的关系及对病情进展的影响研究

Relationship between long non-coding RNA expression and vascular endothelial function in lung adenocarcinoma and its influence on disease progress

摘要:

目的 观察长链非编码RNA（lncRNA）与肺腺癌血管内皮功能的关系及对病情进展的影响。方法 本文为回顾性研究，病例纳入南阳医学高等专科学校附属中医院2020年5月至2022年10月收治的123例肺腺癌患者，采用实时荧光定量聚合酶链式反应（qPCR）检测入组患者肿瘤组织中的人肺腺癌转移相关转录本1（MALAT1）表达情况，依据受试者工作特征（ROC）曲线分析结果，将60例MALAT1低表达相患者列为A组，将63例MALAT1高表达相患者列为B组，收集并对比两组患者的一般资料、临床资料，经统计学单因素分析、Logistic多因素回归分析归纳影响MALAT1表达的主要因素，经Spearman相关性系数验证MALAT1表达与肺腺癌患者血管内皮功能及病情进展的关联。结果 统计学单因素分析结果显示，两组患者的年龄、肿瘤直径最大值、肿瘤数目等一般资料以及肿瘤分化程度、肿瘤浸润深度、区域淋巴结受累情况、远处转移情况、血管内皮功能等临床资料均差异有统计学意义（P<0.05）。Logistic多因素回归分析显示，肿瘤直径最大值>5 cm、多发肿瘤、低分化、肿瘤浸润T3~T4、区域淋巴结受累N1~N2、病灶远处转移M1、血管内皮生长因子（VEGF）≥142 pg/mL、血小板衍化生长因子B（PDGF-B）≥200 pg/mL为影响肺腺癌MALAT1表达的主要因素。经Spearman相关性系数检验，MALAT1表达与肿瘤分化程度负相关，与肿瘤浸润深度、淋巴结受累情况、远处转移情况、VEGF表达、PDGF-B正相关。结论 MALAT1表达水平会随肺腺癌患者病情进展、血管内皮功能损伤加剧而不断上升，敲低MALAT1表达能有效改善血管内皮细胞功能并抑制病情恶化，MALAT1有望成为治疗肺腺癌的lncRNA新型靶点。

Abstract:

Objective To observe the relationship between long non-coding RNA (lncRNA) and vascular endothelial function of adenocarcinoma of the lung and its influence on disease progression.Methods This is a retrospective study. The case was included from May 2020 to October 2022. The study object was 123 patients with adenocarcinoma of the lung. The expression of metastasis associated lung adenocarcinoma transcript 1 (MALAT1) in tumor tissue of enrolled patients was detected by quantitative real-time PCR (qPCR). According to the reciever operating characteristic (ROC) curve analysis results, 60 patients with low expression of MALAT1 were classified as Group A, and 63 patients with high expression of MALAT1 were classified as Group B. The general data and clinical data of the patients in the two groups were collected and compared. Logistic multi-factor regression analysis summarized the main factors affecting the expression of MALAT1. Spearman correlation coefficient was used to verify the correlation between the expression of MALAT1 and vascular endothelial function and disease progression in patients with lung adenocarcinoma.Results The results of statistical univariate analysis showed that there were certain differences in general information such as age, maximum tumor diameter, number of tumors, as well as clinical data such as tumor differentiation, tumor infiltration depth, regional lymph node involvement, distant metastasis, and vascular endothelial function between the two groups of patients (P<0.05). Logistic regression analysis showed that the main factors affecting the expression of MALAT1 in adenocarcinoma of the lung were the maximum tumor diameter >5 cm, multiple tumors, poor differentiation, tumor invasion T3–T4, regional lymph node involvement N1–N2, distant metastasis M1, vascular endothelial growth factor (VEGF) ≥142 pg/mL, platelet-derived growth factor B (PDGF-B) ≥200 pg/mL. After Spearman correlation coefficient test, the expression of MALAT1 was negatively correlated with the degree of tumor differentiation, but positively correlated with tumor infiltration depth, lymph node involvement, distant metastasis, VEGF expression, and PDGF-B.Conclusion The expression level of MALAT1 will continue to rise with the progression of lung adenocarcinoma patients and the worsening of vascular endothelial function. Knocking down the expression of MALAT1 can effectively improve the function of vascular endothelial cells and inhibit the deterioration of disease. MALAT1 is expected to become a new target for adenocarcinoma of the lung.